2. Search Result
Search Result
Results for "

BCL

" in MedChemExpress (MCE) Product Catalog:

703

Inhibitors & Agonists

2

Screening Libraries

6

Biochemical Assay Reagents

27

Peptides

1

MCE Kits

4

Inhibitory Antibodies

122

Natural
Products

25

Recombinant Proteins

14

Isotope-Labeled Compounds

80

Antibodies

1

Click Chemistry

64

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-117288
    S55746
    1 Publications Verification

    BCL201

    		 Bcl-2 Family Cancer
    S55746 (BCL201) is a potent, orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM and a Kd of 3.9 nM. S55746 (BCL201) has antitumor activity with low toxicity .
    S55746
  • HY-129179
    Lisaftoclax
    1 Publications Verification

    APG-2575; BCL-2/BCL-xl inhibitor 1

    		 Bcl-2 Family Cancer
    Lisaftoclax (compound 6) is a dual Bcl-2 and Bcl-xl inhibitor with anti-tumor activity, extracted from patent WO2018027097A1. Lisaftoclax exhibits IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively .
    Lisaftoclax
  • HY-156595
    BCL6-IN-13

    		BCL6 Neurological Disease
    BCL6-IN-13 (compound I-94) inhibits BCL6 with an IC50 of 2 nM .
    BCL6-IN-13
  • HY-122829
    BCL6 PROTAC 1

    		PROTACs BCL6 Cancer
    BCL6 PROTAC 1 is a selective B-cell lymphoma 6 (BCL6) PROTAC. BCL6 PROTAC 1 inhibits BCL6 cell reporter with an IC50 value of 8.8 µM. BCL6 PROTAC 1 significantly degrades BCL6 in diffuse large B-cell lymphoma (DLBCL) cell lines. BCL6 PROTAC 1 can be used in tumor related research .
    BCL6 PROTAC 1
  • HY-12908
    Bcl-xL antagonist 2

    		Bcl-2 Family Apoptosis Cancer
    Bcl-xL antagonist 2 is a potent, selective, and orally active antagonist of BCL-XL with an IC50 and Ki of 0.091 μM and 65 nM, respectively. Bcl-xL antagonist 2 promotes the apoptosis of cancer cells. Bcl-xL antagonist 2 has the potential for the research of the chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL) .
    Bcl-xL antagonist 2
  • HY-115532
    BCL6-IN-7

    		Bcl-2 Family Inflammation/Immunology Cancer
    BCL6-IN-7 is a potent BCL6−corepressor interaction inhibitor .
    BCL6-IN-7
  • HY-143653
    BCL6-IN-6

    		BCL6 Cancer
    BCL6-IN-6 is a potent inhibitor of transcriptional repressor B-cell lymphoma 6 (BCL6). BCL6-IN-6 significantly blocks the interaction of BCL6 with its corepressors and reactivates BCL6 target genes in a dose-dependent manner. BCL6-IN-6 has the potential for the research of diffuse large B-cell lymphoma (DLBCL) .
    BCL6-IN-6
  • HY-135273
    A-1211212

    BCL2-IN-1

    		 Bcl-2 Family Cancer
    A-1211212 (BCL2-IN-1), a chemical probe, is a potent Bcl-2 inhibitor. BCL2-IN-1 binds Bcl-2 with a Ki of <0.01 nM .
    A-1211212
  • HY-117288A
    S55746 hydrochloride
    1 Publications Verification

    BCL201 hydrochloride

    		 Bcl-2 Family Cancer
    S55746 hydrochloride (BCL201 hydrochloride) is a potent, orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM and a Kd of 3.9 nM. S55746 hydrochloride (BCL201 hydrochloride) has antitumor activity with low toxicity .
    S55746 hydrochloride
  • HY-170406
    BCL-XL-IN-3

    		Bcl-2 Family Cancer
    BCL-XL-IN-3 (Compound 11) is an inhibitor for BCL-XL with a Ki < 0.01 nM. BCL-XL-IN-3 inhibits the cell viability in normal Molt-4 and Digitonin (HY-N4000)-permeabilized Molt-4 with EC50 of 77.8 nM and 0.07 nM. BCL-XL-IN-3 can be used as ADC toxin for synthesis of Clezutoclax (HY-137774) .
    BCL-XL-IN-3
  • HY-178777
    BCL6-760

    		PROTACs BCL6 Cancer
    BCL6-760 is an orally active BCL-6 PROTAC degrader with an EC50 of 0.8 nM. BCL6-760 only degrades BCL6 and has no effect on other CRBN substrates. BCL6-760 demonstrates significant efficacy in the orthotopic xenograft mouse model of OCI-LY-1 tumors. BCL6-760 can be used in the research of diffuse Large B-cell Lymphoma (DLBCL) (Pink: BCL-6 ligand (HY-179317); Blue: CRBN ligand (HY-179305); Black: Linker) .
    BCL6-760
  • HY-135275
    BCL-XL-IN-4

    		Bcl-2 Family Cancer
    BCL-XL-IN-4 (compound 10) is a potent and selective BCL-XL inhibitor with Ki values of 0.042, 170 nM for BCL-XL, BCL-2, respectively. BCL-XL-IN-4 shows cytotoxicity .
    BCL-XL-IN-4
  • HY-177755
    BCL6-IN-10

    		Molecular Glues BCL6 Cancer
    BCL6-IN-10 (Compound 6) is a selective partially degradable molecular glue inhibitor that targets the BTB domain of BCL6 with an IC50 of 4 nM. BCL6-IN-10 shows anti-proliferative effect in diffuse large B-cell lymphoma (DLBCL) cell lines. BCL6-IN-10 can be used for the research of cancer .
    BCL6-IN-10
  • HY-119402
    TP-021
    1 Publications Verification

    BCL6-IN-8c

    		 Bcl-2 Family Cancer
    TP-021 (BCL6-IN-8c), a chemical probe, is a potent and orally active B-cell lymphoma 6 (BCL6)-corepressor interaction inhibitor with an IC50 of 0.10 μM in cell-free enzyme-linked immunosorbent assay .
    TP-021
  • HY-RS01438
    BCL6 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    BCL6 Human Pre-designed siRNA Set A contains three designed siRNAs for BCL6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    BCL6 Human Pre-designed siRNA Set A
    BCL6 Human Pre-designed siRNA Set A
  • HY-161415
    BCL-xL/BCL-2 ligand 1

    		Ligands for E3 Ligase Cancer
    BCL-xL/BCL-2 ligand 1 (compound 72-1) is a BCL-xL and BCL-2 protein ligand. BCL-xL/BCL-2 ligand 1 can be connected to the E3 ligase by a linker to form PROTACs (HY-161410) .
    BCL-xL/BCL-2 ligand 1
  • HY-131247
    Bcl-2-IN-2

    		Bcl-2 Family Inflammation/Immunology Cancer
    Bcl-2-IN-2 is a potent and selective Bcl-2 inhibitor with an IC50 of 0.034 nM and also inhibits Bcl-xL with an IC50 of 43 nM, showing >1000-fold selectivity for Bcl-2 over Bcl-xL .
    Bcl-2-IN-2
  • HY-153953
    Bcl-2-IN-11

    		Bcl-2 Family Cancer
    Bcl-2-IN-11 (compound 6) is a potent and selective Bcl-2 activity inhibitor, with an IC50 of 0.9 nM. Bcl-2-IN-11 shows weak inhibition of Bcl-xl (IC50 > 1000 nM). Bcl-2-IN-11 can be used for the research of a variety of cancers caused by abnormal overexpression of Bcl-2 family proteins: especially malignant hematologic diseases of acute lymphoid leukemia, etc. Bcl-2-IN-11 can also avoid toxic side effects caused by Bcl-xl inhibition, such as thrombocytopenia .
    Bcl-2-IN-11
  • HY-149009
    Bcl-2-IN-9

    		Bcl-2 Family Apoptosis Cancer
    Bcl-2-IN-9 is a novel proapoptotic Bcl-2 inhibitor with IC50 value of 2.9 μM and low cytotoxic. Bcl-2-IN-9 mediates apoptosis by down-regulating expression of Bcl-2 in cancer cells and has a high selectivity against leukemia cells .
    Bcl-2-IN-9
  • HY-143872
    Bcl-2-IN-4

    		Bcl-2 Family Cancer
    Bcl-2-IN-4 is a potent, orally active and selective Bcl-2 inhibitor with an IC50 of 1.5 nM. Bcl-2-IN-4 displays >200-fold selectivity over Bcl-xL (IC50 of 411 nM). Bcl-2-IN-4 inhibits RS4; 11 cell proliferation with an IC50 of 2.7 nM (WO2021180040A1; compound 2) .
    Bcl-2-IN-4
  • HY-136640
    BCL6-IN-4

    		Bcl-2 Family Cancer
    BCL6-IN-4 is a potent B-cell lymphoma 6 (BCL6) inhibitor with an IC50 of 97 nM. BCL6-IN-4 has anti-tumor activities .
    BCL6-IN-4
  • HY-160108
    Bcl-2-IN-17

    		Bcl-2 Family Others
    Bcl-2-IN-17 is a Bcl2 inhibitor and can be used for the research of diseases associated with Bcl anti-apoptotic protein .
    Bcl-2-IN-17
  • HY-177756
    BCL6-IN-11

    		BCL6 Cancer
    BCL6-IN-11 (Compound 8) is an efficient inhibitor that induces partial degradation of BCL6 with its IC50 value for inhibiting the interaction between BCL6 and its co-inhibitory proteins (such as NCOR1) of 6 nM. BCL6-IN-11 can induce approximately 52% degradation of BCL6 after being treated with 5 μM concentration for 90 minutes, and thus is also classified as a partial degrader. BCL6-IN-11 can be used for the study of lymphoma .
    BCL6-IN-11
  • HY-178804
    BCL6 ligand-5

    		Ligands for Target Protein for PROTAC BCL6 Cancer
    BCL6 ligand-5 (Compound 37) is a BCL6 ligand. BCL6 ligand-5 can be used as a ligand for target protein for PROTAC to develop and design degraders for PROTAC BCL6, such as PROTAC BCL6 Degrader-2 (HY-178803). BCL6 ligand-5 can also be used in tumor research .
    BCL6 ligand-5
  • HY-176382
    BCL6 ligand-4

    		Ligands for Target Protein for PROTAC BCL6 Cancer
    BCL6 ligand-4 is an BCL6 ligand that can be used in the synthesis of PROTACs, such as BCL6 PROTAC 1 (HY-122829) .
    BCL6 ligand-4
  • HY-174878
    BCL-xL ligand 2

    		Ligands for Target Protein for PROTAC Bcl-2 Family Cancer
    BCL-xL ligand 2 is a ligand for BCL-xL. BCL-xL ligand 2 can be conjugated with E3 ligase Ligand (HY-138793) and linker to synthesize Bcl-xL PROTAC degrader PZ671 (HY-174876) .
    BCL-xL ligand 2
  • HY-153594
    Bcl-B inhibitor 1

    		Bcl-2 Family Cancer
    Bcl-B inhibitor 1 is a Bcl-B inhibitor .
    Bcl-B inhibitor 1
  • HY-136714
    Bcl-2-IN-3

    		Bcl-2 Family Cancer
    Bcl-2-IN-3 (Compound 10) is a Bcl-2 inhibitor. Bcl-2-IN-3 can be used for the research of cancer .
    Bcl-2-IN-3
  • HY-149623
    Bcl-2-IN-13

    		Bcl-2 Family Cancer
    Bcl-2-IN-13 is a Bcl-2 inhibitor with an IC50 value of 17 nM. Bcl-2-IN-13 can be used in cancer research .
    Bcl-2-IN-13
  • HY-149622
    Bcl-2-IN-12

    		Bcl-2 Family Cancer
    Bcl-2-IN-12 (Compound 1) is a Bcl-2 inhibitor (IC50: 6 nM). Bcl-2-IN-12 can be used for cancer research .
    Bcl-2-IN-12
  • HY-143873
    Bcl-2-IN-5

    		Bcl-2 Family Cancer
    Bcl-2-IN-5 is a BCL-2 inhibitor with IC50s of 0.12 nM, 0.14 nM and 0.22 nM for Bcl-2 wild type, Bcl-2 D103Y and Bcl-2 G101V, respectively. Bcl-2-IN-5 inhibits the cell growth with IC50 values of 0.2 nM and 0.44 nM for Bcl 2-G101V knock-in RS4; 11 and RS4; 11 cells, respectively (WO2021208963A1; Example 155) .
    Bcl-2-IN-5
  • HY-169083
    Bcl-2-IN-22

    		Apoptosis Bcl-2 Family Cancer
    Bcl-2-IN-22 (compound 1) is a gold(I) NHC complex with anticancer activity. Bcl-2-IN-22 induces apoptosis via the mitochondrial pathway with an IC50 value of 0.014 μM. In addition, Bcl-2-IN-22 targets BCL-2 family members and exhibits pro-apoptosis and resensitization properties in multidrug-resistant leukemia cells that overexpress BCL-2 .
    Bcl-2-IN-22
  • HY-149624
    Bcl-2-IN-14

    		Bcl-2 Family Cancer
    Bcl-2-IN-14 (Compound 13c) is a BCL-2 inhibitor with an IC50 value of 0.471 μM. Bcl-2-IN-14 can be used in cancer research .
    Bcl-2-IN-14
  • HY-149625
    Bcl-2-IN-15

    		Bcl-2 Family Cancer
    Bcl-2-IN-15 (Compound 13d)) is a Bcl-2 inhibitor (IC50: 363 nM). Bcl-2-IN-15 inhibits the proliferation ofNCI leukemia cancer cell line .
    Bcl-2-IN-15
  • HY-176219
    Bcl-2-IN-23

    		Bcl-2 Family Apoptosis Necroptosis Cancer
    Bcl-2-IN-23 (compound 5) is a selective inhibitor targeting Bcl-2. The IC50 of Bcl-2-IN-23 in HTB-140, HeLa and SW620 cells is 25.7-33.7 μM. Bcl-2-IN-23 can non-covalently competitively bind to Bcl-2 protein, significantly reduce its expression, and induce late apoptosis and necroptosis of cancer cells. Bcl-2-IN-23 enhances the sensitivity of cancer cells to apoptosis and reduces the release of IL-6 inflammatory factors by disrupting the Bcl-2-mediated mitochondrial apoptosis inhibition pathway. Bcl-2-IN-23 can be used for anti-apoptosis research of malignant tumors such as melanoma, cervical cancer, and colorectal cancer .
    Bcl-2-IN-23
  • HY-163308
    Bcl-2-IN-18

    		Bcl-2 Family Cancer
    Bcl-2-IN-18 (Compound 23) is a breast cancer Bcl-2 inhibitor with a IC50 value of 4.7 μM for MCF-7. Bcl-2-IN-18 has antitumor activity .
    Bcl-2-IN-18
  • HY-163309
    Bcl-2-IN-19

    		Bcl-2 Family Cancer
    Bcl-2-IN-19 (compound 27) is a potent Bcl-2 inhibitor for targeting breast cancer .
    Bcl-2-IN-19
  • HY-179317
    BCL6 ligand-8

    		Ligands for Target Protein for PROTAC BCL6 Cancer
    BCL6 ligand-8 is a PROTAC target protein ligand that can be used for synthesis of PROTACs, such as BCL6-760 (HY-178777). BCL6-760 is a potent BCL6 PROTAC degrader with anti-tumor activity .
    BCL6 ligand-8
  • HY-162820
    Bcl-2-IN-21

    		Bcl-2 Family Cancer
    Bcl-2-IN-21 (compound C1) is an iridium compound with anticancer activity that targets and inhibits Bcl-2. Bcl-2-IN-21 inhibits colony formation of cancer cells and induces elevated levels of Bax and caspase 3 .
    Bcl-2-IN-21
  • HY-144791
    Bcl-2-IN-6

    		Bcl-2 Family MDM-2/p53 Caspase Apoptosis Cancer
    Bcl-2-IN-6 (compound 10) is a potent Bcl-2 (B-cell lymphoma-2) inhibitor. Bcl-2-IN-7 down-regulates the expression of Bcl-2, and increases the expression of p53, Bax, and caspase-7 mRNA. Bcl-2-IN-7 induces cell cycle arrest and apoptosis in breast cancer MCF-7 cells. Bcl-2-IN-7 shows good anticancer activity, with IC50 values of 20.91, 22.30, 42.29, and 48.00 μM against MCF-7, LoVo, HepG2, and A549 cell lines, respectively .
    Bcl-2-IN-6
  • HY-144792
    Bcl-2-IN-7

    		Bcl-2 Family MDM-2/p53 Caspase Apoptosis Cancer
    Bcl-2-IN-7 (compound 6) is a potent Bcl-2 (B-cell lymphoma-2) inhibitor. Bcl-2-IN-7 down-regulates the expression of Bcl-2, and increases the expression of p53, Bax, and caspase-7 mRNA. Bcl-2-IN-7 induces cell cycle arrest and apoptosis in breast cancer MCF-7 cells. Bcl-2-IN-7 shows good anticancer activity, with IC50 values of 20.17, 22.64, 45.57, and 51.50 μM against MCF-7, LoVo, HepG2, and A549 cell lines, respectively .
    Bcl-2-IN-7
  • HY-146183
    BCL6-IN-9

    		Bcl-2 Family Cancer
    BCL6-IN-9 (compound 1) is a potent B-cell lymphoma 6 protein (BCL6) inhibitor, with an IC50 of 3.9 nM. BCL6-IN-9 can be used for the research of cancer .
    BCL6-IN-9
  • HY-150540
    Bcl-2-IN-10

    		Bcl-2 Family Apoptosis Cancer
    Bcl-2-IN-10 is an active Bcl-2 inhibitor that can release up to four nitric oxide (NO) molecules. Bcl-2-IN-10 has cytotoxic activities against cancer cells, such as human leukemia, breast cancer and lung cancer. Bcl-2-IN-10 induces cell apopotosis and arrest cell cycle of G2/M phase, and can be used in cancer-related research .
    Bcl-2-IN-10
  • HY-144428
    Bcl-2/Mcl-1-IN-2

    		Bcl-2 Family Cancer
    Bcl-2/Mcl-1-IN-2 (compound 2) is a Bcl-2/Mcl-1 inhibitor, with Kis of 0.88 μM and 4.70 μM for Mcl-1 and Bcl-2, respectively. Bcl-2/Mcl-1-IN-2 can be used for the research of cancer .
    Bcl-2/Mcl-1-IN-2
  • HY-144430
    Bcl-2/Mcl-1-IN-1

    		Bcl-2 Family Cancer
    Bcl-2/Mcl-1-IN-1 (compound 3) is a Bcl-2/Mcl-1 inhibitor, with Kis of 1.19 μM and 4.53 μM for Mcl-1 and Bcl-2, respectively. Bcl-2/Mcl-1-IN-1 can be used for the research of cancer .
    Bcl-2/Mcl-1-IN-1
  • HY-144431
    Bcl-2/Mcl-1-IN-3

    		Bcl-2 Family Cancer
    Bcl-2/Mcl-1-IN-3 (compound 1) is a Bcl-2/Mcl-1 inhibitor, with Kis of 0.14 μM and 0.23 μM for Mcl-1 and Bcl-2, respectively. Bcl-2/Mcl-1-IN-3 can be used for the research of cancer .
    Bcl-2/Mcl-1-IN-3
  • HY-136774
    BCL6-IN-5

    		Bcl-2 Family Cancer
    BCL6-IN-5 is a potent BCL6 inhibitor exacted from patent WO2018215801A1, example 1n, has a pIC50 of 5.82 .
    BCL6-IN-5
  • HY-161786
    Bcl-2-IN-20

    		Bcl-2 Family Apoptosis Reactive Oxygen Species (ROS) Cancer
    Bcl-2-IN-20 (Compound 81) is an inhibitor for Bcl-2 with IC50 <10 μM (79.1% inhibition at 9 μM). Bcl-2-IN-20 exhibits cytotoxicity in SK-MEL-28 (IC50>10 μM), A549 (IC50=6.1 μM), HepG2 (IC50>10 μM), MCF-7 (IC50=8.9 μM), HCT116 (IC50>10 μM) and HEK-293 (IC50=14.1 μM). Bcl-2-IN-20 promotes the ROS production, induces apoptosis and DNA damage .
    Bcl-2-IN-20
  • HY-159513
    Bcl-2/Mcl-1-IN-4

    		Bcl-2 Family Apoptosis Cancer
    Bcl-2/Mcl-1-IN-4 (compound 20) is a dual inhibitor targeting Bcl-2 (Ki=0.49 μM) and Mcl-1 (Ki=0.51 μM). Bcl-2/Mcl-1-IN-4 significantly inhibits cancer cell proliferation and effectively induces apoptosis in U937 cells. Bcl-2/Mcl-1-IN-4 can be used in cancer research .
    Bcl-2/Mcl-1-IN-4
  • HY-161990
    BCL6 ligand-2

    		Ligands for Target Protein for PROTAC Cancer
    BCL6 ligand-2 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). BCL6 ligand-2 can be used for synthesis DZ-837 (HY-161989) .
    BCL6 ligand-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: